ATE279947T1 - Immunglobulinähnliche domäne mit erhöhten halbwertszeiten - Google Patents

Immunglobulinähnliche domäne mit erhöhten halbwertszeiten

Info

Publication number: ATE279947T1
Authority: AT; Austria
Prior art keywords: domains; antibody; increased; half lives; immunoglobulin
Prior art date: 1996-03-18

Application number

AT97907993T

Other languages

German (de)

English (en)

Inventor

Elizabeth Sally Ward

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-18

Filing date

1997-03-03

Publication date

2004-11-15

1997-03-03 Application filed by Univ Texas filed Critical Univ Texas

2004-11-15 Application granted granted Critical

2004-11-15 Publication of ATE279947T1 publication Critical patent/ATE279947T1/de

Links

102000016844 Immunoglobulin-like domains Human genes 0.000 title abstract 2
108050006430 Immunoglobulin-like domains Proteins 0.000 title abstract 2
102000037865 fusion proteins Human genes 0.000 abstract 2
108020001507 fusion proteins Proteins 0.000 abstract 2
238000001727 in vivo Methods 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000002703 mutagenesis Methods 0.000 abstract 1
231100000350 mutagenesis Toxicity 0.000 abstract 1
108020001580 protein domains Proteins 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT97907993T 1996-03-18 1997-03-03 Immunglobulinähnliche domäne mit erhöhten halbwertszeiten ATE279947T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1356396P	1996-03-18	1996-03-18
PCT/US1997/003321 WO1997034631A1 (en)	1996-03-18	1997-03-03	Immunoglobin-like domains with increased half lives

Publications (1)

Publication Number	Publication Date
ATE279947T1 true ATE279947T1 (de)	2004-11-15

Family

ID=21760590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97907993T ATE279947T1 (de)	1996-03-18	1997-03-03	Immunglobulinähnliche domäne mit erhöhten halbwertszeiten

Country Status (7)

Country	Link
EP (1)	EP0904107B1 (2)
JP (1)	JP4046354B2 (2)
AT (1)	ATE279947T1 (2)
AU (1)	AU728657B2 (2)
CA (1)	CA2249195A1 (2)
DE (1)	DE69731289D1 (2)
WO (1)	WO1997034631A1 (2)

Families Citing this family (837)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6852508B1 (en)	1997-02-28	2005-02-08	Genetics Institute, Llc	Chemokine with amino-terminal modifications
US6100387A (en) *	1997-02-28	2000-08-08	Genetics Institute, Inc.	Chimeric polypeptides containing chemokine domains
EP1489100B1 (en)	1997-12-08	2016-06-15	Merck Patent GmbH	Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
EP1105427A2 (en) *	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
PT1783222E (pt)	1998-10-23	2012-07-26	Kirin Amgen Inc	Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
GB9824632D0 (en)	1998-11-10	1999-01-06	Celltech Therapeutics Ltd	Biological compounds
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
HU230769B1 (hu)	1999-01-15	2018-03-28	Genentech Inc.	Módosított effektor-funkciójú polipeptid-változatok
GB9908263D0 (en) *	1999-04-13	1999-06-02	Binding Site The Limited	Eliciting improved immune responses
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja)	1999-08-09	2011-10-12	メルクパテントゲーエムベーハー	複合サイトカイン−抗体複合体
US7459540B1 (en)	1999-09-07	2008-12-02	Amgen Inc.	Fibroblast growth factor-like polypeptides
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1228214A2 (en)	1999-11-12	2002-08-07	MERCK PATENT GmbH	Erythropoietin forms with improved properties
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
HUP0204475A2 (en)	2000-02-11	2003-04-28	Merck Patent Gmbh	Enhancing the circulating half-life of antibody-based fusion proteins
AU2001257173B2 (en)	2000-04-21	2005-09-22	Amgen Inc.	Apo-ai/aii peptide derivatives
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
US20020086018A1 (en)	2000-05-12	2002-07-04	Theill Lars Eyde	Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
DE60129695T2 (de)	2000-06-29	2008-06-05	Merck Patent Gmbh	Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US6818216B2 (en)	2000-11-28	2004-11-16	Medimmune, Inc.	Anti-RSV antibodies
EP2412384A1 (en)	2000-11-28	2012-02-01	MedImmune, LLC	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2008201419C1 (en) *	2000-12-12	2018-01-18	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en)	2000-12-12	2010-02-09	Medimmune, Llc	Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2011253690C1 (en) *	2000-12-12	2018-01-18	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
AU2002248571B2 (en)	2001-03-07	2007-01-18	Merck Patent Gmbh	Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en)	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
US7256257B2 (en)	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
PT1383785E (pt)	2001-05-03	2011-06-28	Merck Patent Gmbh	Anticorpo recombinante específico de tumores e utilização deste
ATE549354T1 (de)	2001-05-11	2012-03-15	Amgen Inc	Peptide und damit zusammenhängende an tall-1 bindende moleküle
US7138370B2 (en)	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
US7332474B2 (en)	2001-10-11	2008-02-19	Amgen Inc.	Peptides and related compounds having thrombopoietic activity
PT1454138E (pt)	2001-12-04	2012-03-28	Merck Patent Gmbh	Imunocitoquinas com seletividade modulada
US7662925B2 (en)	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20040028685A1 (en)	2002-05-10	2004-02-12	Kinch Michael S.	EphA2 monoclonal antibodies and methods of use thereof
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
SI1545613T1 (sl)	2002-07-31	2011-11-30	Seattle Genetics Inc	Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US8187593B2 (en)	2002-08-14	2012-05-29	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en)	2002-08-14	2013-09-10	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en)	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en)	2002-08-14	2015-03-03	Macrogenics Inc.	FcγRIIB specific antibodies and methods of use thereof
AU2003259995B2 (en)	2002-08-28	2009-07-02	Immunex Corporation	Compositions and methods for treating cardiovascular disease
US6919426B2 (en)	2002-09-19	2005-07-19	Amgen Inc.	Peptides and related molecules that modulate nerve growth factor activity
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en)	2002-10-15	2008-04-29	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN100432105C (zh)	2002-12-17	2008-11-12	默克专利有限公司	与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
JP2006524039A (ja)	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en)	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US20090010920A1 (en)	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
JP4685764B2 (ja) *	2003-04-10	2011-05-18	アボットバイオセラピューティクスコーポレイション	変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
JP4764818B2 (ja)	2003-04-11	2011-09-07	メディミューン，エルエルシー	組換えｉｌ−９抗体およびその使用
US9051373B2 (en)	2003-05-02	2015-06-09	Xencor, Inc.	Optimized Fc variants
PT1624891E (pt)	2003-05-06	2010-01-05	Syntonix Pharmaceuticals Inc	Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
EP1648935A2 (en)	2003-07-25	2006-04-26	Amgen Inc.	Antagonists and agonists of ldcam and methods of use
CN1871259A (zh)	2003-08-22	2006-11-29	比奥根艾迪克Ma公司	具有改变的效应物功能的经改进的抗体和制备它的方法
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US8101720B2 (en)	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
JP2007531707A (ja)	2003-10-15	2007-11-08	ピーディーエルバイオファーマ，インコーポレイテッド	ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
AU2004287431B2 (en)	2003-10-27	2010-03-11	Amgen Inc.	Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
US7498298B2 (en)	2003-11-06	2009-03-03	Seattle Genetics, Inc.	Monomethylvaline compounds capable of conjugation to ligands
ATE555133T1 (de)	2003-11-13	2012-05-15	Hanmi Holdings Co Ltd	Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
KR101135244B1 (ko)	2007-11-29	2012-04-24	한미사이언스 주식회사	인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
WO2005058961A2 (en)	2003-12-12	2005-06-30	Amgen Inc.	Antibodies specific for human galanin, and uses thereof
CA2551915C (en)	2003-12-30	2015-06-23	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Il-7 fusion proteins
JP2008504008A (ja)	2003-12-31	2008-02-14	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
DK2311873T3 (en)	2004-01-07	2018-11-26	Novartis Vaccines & Diagnostics Inc	M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
PL1706428T3 (pl)	2004-01-22	2010-02-26	Merck Patent Gmbh	Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
JP2008504012A (ja)	2004-01-28	2008-02-14	シントニックス・ファーマシューティカルズ・インコーポレーテッド	不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
EP1737890A2 (en)	2004-03-24	2007-01-03	Xencor, Inc.	Immunoglobulin variants outside the fc region
WO2005110474A2 (en)	2004-05-10	2005-11-24	Macrogenics, Inc.	HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
SI2612862T1 (sl)	2004-05-13	2017-04-26	Icos Corporation	Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
KR101699142B1 (ko)	2004-06-18	2017-01-23	암브룩스, 인코포레이티드	신규 항원-결합 폴리펩티드 및 이의 용도
WO2006010057A2 (en)	2004-07-08	2006-01-26	Amgen Inc.	Therapeutic peptides
US20150010550A1 (en)	2004-07-15	2015-01-08	Xencor, Inc.	OPTIMIZED Fc VARIANTS
EA014226B1 (ru)	2004-07-26	2010-10-29	Байоджен Айдек Ма Инк.	Антитела к cd154, их фрагменты и способы применения антител и фрагментов
PL1776384T3 (pl)	2004-08-04	2013-10-31	Mentrik Biotech Llc	WARIANTY REGIONÓW Fc
WO2006034292A2 (en)	2004-09-21	2006-03-30	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
EA011879B1 (ru)	2004-09-24	2009-06-30	Эмджин Инк.	МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
US20060121042A1 (en)	2004-10-27	2006-06-08	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1810035A4 (en)	2004-11-10	2010-03-17	Macrogenics Inc	GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
WO2006132670A2 (en)	2004-11-12	2006-12-14	Seattle Genetics, Inc.	Auristatins having an aminobenzoic acid unit at the n terminus
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
US8802820B2 (en)	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8367805B2 (en)	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
DK1817340T3 (da)	2004-11-12	2012-08-13	Xencor Inc	Fc-varianter med ændret binding til fcrn
CN101072793B (zh)	2004-12-09	2012-06-20	默克专利有限公司	具有降低的免疫原性的il-7变体
CN103555733A (zh)	2005-01-05	2014-02-05	F-星生物技术研究与开发有限公司	分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
KR100754667B1 (ko)	2005-04-08	2007-09-03	한미약품 주식회사	비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP3479844B1 (en)	2005-04-15	2023-11-22	MacroGenics, Inc.	Covalent diabodies and uses thereof
US11254748B2 (en)	2005-04-15	2022-02-22	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9963510B2 (en)	2005-04-15	2018-05-08	Macrogenics, Inc.	Covalent diabodies and uses thereof
US9284375B2 (en)	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
US7833979B2 (en)	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
CN102321174B (zh)	2005-05-06	2013-10-16	津莫吉尼蒂克斯公司	Il-31单克隆抗体及使用方法
DK1899378T3 (da)	2005-06-21	2010-02-01	Xoma Technology Ltd	IL-1 beta-bindende antistoffer og fragmenter deraf
EP1893647A2 (en)	2005-06-23	2008-03-05	MedImmune, Inc.	Antibody formulations having optimized aggregation and fragmentation profiles
JP5171621B2 (ja)	2005-07-07	2013-03-27	シアトルジェネティックス，インコーポレイテッド	フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
WO2007008943A2 (en)	2005-07-08	2007-01-18	Xencor, Inc.	Optimized anti-ep-cam antibodies
HUE035853T2 (en)	2005-07-18	2018-05-28	Seattle Genetics Inc	Beta-glucuronide-linker-drug conjugates
WO2007016285A2 (en)	2005-07-28	2007-02-08	Novartis Ag	M-csf specific monoclonal antibody and uses thereof
HUE029465T2 (en)	2005-08-10	2017-02-28	Macrogenics Inc	Identification and engineering of antibodies with variant Fc regions and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en)	2005-10-06	2007-04-19	Xencor, Inc.	Optimized anti-cd30 antibodies
EA015860B1 (ru)	2005-10-13	2011-12-30	Хьюман Дженом Сайенсиз, Инк.	Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
AR056142A1 (es)	2005-10-21	2007-09-19	Amgen Inc	Metodos para generar el anticuerpo igg monovalente
AU2006340750B2 (en)	2005-11-28	2013-03-07	Zymogenetics, Inc.	IL-21 antagonists
CA2634080A1 (en)	2005-12-20	2007-06-28	Arana Therapeutics Limited	Anti-inflammatory dab
US9012605B2 (en)	2006-01-23	2015-04-21	Amgen Inc.	Crystalline polypeptides
CN101400703B (zh)	2006-02-01	2013-05-08	赛法隆澳大利亚控股有限公司	结构域抗体构建体
JP2009529915A (ja)	2006-03-20	2009-08-27	ゾーマテクノロジーリミテッド	ガストリン物質に対して特異的なヒト抗体および方法
ES2892925T3 (es)	2006-03-31	2022-02-07	Chugai Pharmaceutical Co Ltd	Métodos para controlar la farmacocinética en sangre de anticuerpos
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
TWI395754B (zh)	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
EP2027291A2 (en)	2006-04-27	2009-02-25	Pikamab, Inc.	Methods and compositions for antibody therapy
US7786270B2 (en)	2006-05-26	2010-08-31	Macrogenics, Inc.	Humanized FcγRIIB-specific antibodies and methods of use thereof
SG10201504662WA (en)	2006-06-14	2015-07-30	Macrogenics Inc	Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US7981425B2 (en)	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
JP5368301B2 (ja) *	2006-06-22	2013-12-18	ノボ・ノルデイスク・エー／エス	可溶性ヘテロ二量体レセプター及びその使用
HUE030269T2 (en)	2006-06-26	2017-04-28	Macrogenics Inc	FC RIIB-specific antibodies and methods for their use
EP2452683A3 (en)	2006-06-26	2012-08-22	Amgen Inc.	Methods for treating atherosclerosis
WO2008002933A2 (en)	2006-06-26	2008-01-03	Macrogenics, Inc.	Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
AT503902B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von immunglobulinen
AT503861B1 (de)	2006-07-05	2008-06-15	F Star Biotech Forsch & Entw	Verfahren zur manipulation von t-zell-rezeptoren
TW200815474A (en)	2006-08-03	2008-04-01	Astrazeneca Ab	Antibodies alphaVbeta6 and uses thereof
CL2007002225A1 (es)	2006-08-03	2008-04-18	Astrazeneca Ab	Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
EP2057193B1 (en)	2006-08-04	2013-12-18	Novartis AG	Ephb3-specific antibody and uses thereof
EP2054444B1 (en)	2006-08-04	2016-11-02	MedImmune Limited	Antibodies to erbb2
PL2383297T3 (pl)	2006-08-14	2013-06-28	Xencor Inc	Zoptymalizowane przeciwciała ukierunkowane na CD19
AR062435A1 (es)	2006-08-18	2008-11-05	Xoma Technology Ltd	Anticuerpo especifico prlr (receptor de prolactina) y sus usos
ES2439994T3 (es)	2006-08-28	2014-01-27	Kyowa Hakko Kirin Co., Ltd.	Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
DK2594586T3 (en)	2006-09-01	2014-11-17	Zymogenetics Inc	Monoclonal il-31 antibodies and methods of use thereof
WO2008036688A2 (en)	2006-09-18	2008-03-27	Xencor, Inc.	Optimized antibodies that target hm1.24
AU2007313300A1 (en)	2006-10-16	2008-04-24	Medimmune, Llc.	Molecules with reduced half-lives, compositions and uses thereof
PE20081140A1 (es)	2006-10-25	2008-09-22	Amgen Inc	Agentes terapeuticos a base de peptidos derivados de toxinas
HU0700534D0 (en)	2006-11-24	2007-10-29	Mezoegazdasagi Biotechnologiai	Transgenic animal with enhanced immune response and method for the preparation thereof
WO2008070593A2 (en)	2006-12-01	2008-06-12	Seattle Genetics, Inc.	Variant target binding agents and uses thereof
KR101519672B1 (ko)	2006-12-07	2015-05-29	노파르티스 아게	Ｅｐｈｂ３에 대한 길항제 항체
WO2008140603A2 (en)	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
CA2673592C (en)	2006-12-20	2014-03-25	Xoma Technology Ltd.	Methods for the treatment of il-1.beta. related diseases
JP2008169195A (ja)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CA2682292A1 (en)	2007-03-30	2008-10-09	Medimmune, Llc	Aqueous formulation comprising an anti-human interferon alpha antibody
AU2008246442B2 (en)	2007-05-04	2014-07-03	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Engineered rabbit antibody variable domains and uses thereof
DK2160401T3 (da)	2007-05-11	2014-10-20	Altor Bioscience Corp	Fusionsmolekyler og il-15-varianter
HUE036885T2 (hu)	2007-05-14	2018-08-28	Astrazeneca Ab	Eljárás a bazofil-szint csökkentésére
EP2162540A2 (en)	2007-05-22	2010-03-17	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
CA2693053C (en)	2007-05-30	2021-01-05	Xencor, Inc.	Methods and compositions for inhibiting cd32b expressing cells
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
AU2009258063B2 (en)	2007-06-21	2014-09-25	Macrogenics, Inc.	BCR-complex-specific antibodies and methods of using same
EP3241842B1 (en)	2007-06-26	2024-01-31	F-star Therapeutics Limited	Display of binding agents
US20090028857A1 (en)	2007-07-23	2009-01-29	Cell Genesys, Inc.	Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
ES2559353T3 (es)	2007-07-26	2016-02-11	Amgen, Inc	Enzimas lecitina-colesterol aciltransferasa modificadas
KR20100058509A (ko)	2007-07-31	2010-06-03	메디뮨 엘엘씨	다중특이적 에피토프 결합 단백질 및 이의 용도
PE20140196A1 (es)	2007-08-09	2014-03-19	Boehringer Ingelheim Int	Anticuerpos anti-cd37
CN111909273B (zh)	2007-08-29	2024-03-26	塞诺菲-安万特股份有限公司	人源化的抗-cxcr5抗体、其衍生物及它们的应用
WO2009040562A1 (en)	2007-09-26	2009-04-02	Ucb Pharma S.A.	Dual specificity antibody fusions
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
EP2796466B1 (en)	2007-12-07	2017-11-22	ZymoGenetics, Inc.	Humanized antibody molecules specific for IL-31
EP3103813A1 (en)	2007-12-07	2016-12-14	ZymoGenetics, Inc.	Anti-human il-21 monoclonal antibodies
US8795667B2 (en)	2007-12-19	2014-08-05	Macrogenics, Inc.	Compositions for the prevention and treatment of smallpox
US8637029B2 (en)	2007-12-20	2014-01-28	Xoma Technology Ltd.	Methods for the treatment of gout
WO2009085200A2 (en)	2007-12-21	2009-07-09	Amgen Inc.	Anti-amyloid antibodies and uses thereof
RU2529951C2 (ru)	2007-12-26	2014-10-10	Ксенкор, Инк.	ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
JP2011509675A (ja)	2008-01-18	2011-03-31	メディミューン，エルエルシー	部位特異的コンジュゲーションのためのシステイン操作抗体
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
EP2265283B1 (en)	2008-03-18	2014-09-03	Seattle Genetics, Inc.	Auristatin drug linker conjugates
CN107325182A (zh)	2008-04-02	2017-11-07	宏观基因有限公司	HER2/neu‑特异性抗体和其使用方法
KR102057826B1 (ko)	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
BRPI0910622A2 (pt) *	2008-04-25	2020-03-10	Dyax Corp.	ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
EP2113255A1 (en)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Cytotoxic immunoglobulin
EP2296690B1 (en)	2008-06-04	2016-11-30	Amgen, Inc	Fgf21 mutants and uses thereof
EP2307456B1 (en)	2008-06-27	2014-10-15	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
JP5611210B2 (ja)	2008-09-07	2014-10-22	グリコネックスインコーポレイテッド	抗拡張ｉ型スフィンゴ糖脂質抗体、その誘導体および使用
RU2581962C2 (ru)	2008-09-19	2016-04-20	Медиммун Ллк	Нацеленные средства связывания, направленные на dll4, и их применение
EP3524620A1 (en) *	2008-10-14	2019-08-14	Genentech, Inc.	Immunoglobulin variants and uses thereof
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
CN102271683B (zh)	2008-11-13	2014-07-09	吉里德卡利斯托加公司	恶性血液病的治疗
EP2373689A1 (en)	2008-12-12	2011-10-12	MedImmune, LLC	Crystals and structure of a human igg fc variant with enhanced fcrn binding
WO2010072740A2 (en)	2008-12-23	2010-07-01	Astrazeneca Ab	TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2408814B1 (en)	2009-03-20	2018-11-21	Amgen Inc.	Carrier immunoglobulins and uses thereof
CA2756347A1 (en)	2009-03-24	2010-09-30	Gilead Calistoga Llc	Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CN102458410A (zh)	2009-04-20	2012-05-16	吉联亚·卡利斯托加有限责任公司	治疗实体瘤的方法
DK2421898T3 (en)	2009-04-20	2016-05-30	Oxford Biotherapeutics Ltd	Cadherin-17 SPECIFIC ANTIBODIES
EP2421896A1 (en) *	2009-04-22	2012-02-29	Merck Patent GmbH	Antibody fusion proteins with modified fcrn binding sites
HRP20240135T1 (hr)	2009-05-05	2024-04-12	Amgen Inc.	Fgf21 mutanti i njihove upotrebe
EP2427207B1 (en)	2009-05-05	2017-08-16	Amgen, Inc	Fgf21 mutants and uses thereof
WO2010141329A1 (en)	2009-06-01	2010-12-09	Medimmune, Llc	Molecules with extended half-lives and uses thereof
EP2443137B1 (en)	2009-06-15	2015-05-20	Biokine Therapeutics Ltd.	Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
US20120237496A1 (en)	2009-06-19	2012-09-20	Joerg Birkenfeld	Protease variants
AU2010270979B2 (en)	2009-06-22	2015-04-23	Medimmune, Llc	Engineered Fc regions for site-specific conjugation
EA201270184A1 (ru)	2009-07-21	2012-08-30	ГИЛИЭД КАЛИСТОГА ЭлЭлСи	Лечение расстройств печени ингибиторами pi3k
ES2666152T3 (es)	2009-08-13	2018-05-03	The Johns Hopkins University	Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
PL2464664T3 (pl)	2009-08-13	2016-02-29	Crucell Holland Bv	Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
CN102597775A (zh)	2009-09-25	2012-07-18	佐马技术有限公司	筛选方法
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
WO2011044368A1 (en)	2009-10-07	2011-04-14	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2470569A1 (en)	2009-10-13	2012-07-04	Oxford Biotherapeutics Ltd.	Antibodies against epha10
EP2496243A2 (en)	2009-11-04	2012-09-12	Erasmus University Medical Center Rotterdam	Novel compounds for modulating neovascularisation and methods of treatment using these compounds
AU2010321832B2 (en)	2009-11-20	2014-08-14	Amgen Inc.	Anti-Orai1 antigen binding proteins and uses thereof
NZ628923A (en)	2009-11-24	2016-02-26	Medimmune Ltd	Targeted binding agents against b7-h1
UA109888C2 (uk)	2009-12-07	2015-10-26		ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
KR101312829B1 (ko)	2009-12-30	2013-09-27	한화엘앤씨 주식회사	ＨＯ-1 유전자 및 ＴＮＦＲ1-Ｆｃ 유전자를 동시에 발현하는 형질전환 돼지 및 그의 제조 방법
US8362210B2 (en)	2010-01-19	2013-01-29	Xencor, Inc.	Antibody variants with enhanced complement activity
JP5998060B2 (ja)	2010-03-04	2016-09-28	マクロジェニクス，インコーポレーテッド	Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
PH12012501751A1 (en)	2010-03-04	2012-11-12	Macrogenics Inc	Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AR081066A1 (es)	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR081755A1 (es)	2010-04-02	2012-10-17	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
AR080993A1 (es)	2010-04-02	2012-05-30	Hanmi Holdings Co Ltd	Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
US20130101590A1 (en)	2010-04-09	2013-04-25	Heather A. Arnett	Btnl9 proteins, nucleic acids, and antibodies and uses thereof
CA2796055A1 (en)	2010-04-15	2011-10-20	Amgen Inc.	Human fgf receptor and .beta.-klotho binding proteins
KR20130066631A (ko)	2010-05-06	2013-06-20	노파르티스 아게	치료적 저밀도 지단백질-관련 단백질 ６（ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
EP4234698A3 (en)	2010-05-06	2023-11-08	Novartis AG	Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CA2799595C (en)	2010-05-27	2022-08-16	Merck Sharp & Dohme Corp.	Method for preparing antibodies having improved properties
PH12012502244A1 (en)	2010-07-09	2016-09-30	Crucell Holland Bv	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UA126265C2 (uk)	2010-07-09	2022-09-14	Байовератів Терапьютікс Інк.	Поліпептид фактора іх і спосіб його застосування
KR101382593B1 (ko)	2010-07-21	2014-04-10	한미사이언스 주식회사	신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
EP2601216B1 (en)	2010-08-02	2018-01-03	MacroGenics, Inc.	Covalent diabodies and uses thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
NZ607337A (en)	2010-08-20	2015-06-26	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
CA2809369A1 (en)	2010-08-27	2012-03-01	Stem Centrx, Inc.	Notum protein modulators and methods of use
CA2810016A1 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
US11053299B2 (en)	2010-09-21	2021-07-06	Immunity Bio, Inc.	Superkine
CN107880136B (zh)	2010-09-21	2021-11-12	阿尔托生物科学有限公司	多聚体il-15可溶性融合分子与其制造与使用方法
WO2012040518A2 (en)	2010-09-22	2012-03-29	Amgen Inc.	Carrier immunoglobulins and uses thereof
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US9023791B2 (en)	2010-11-19	2015-05-05	Novartis Ag	Fibroblast growth factor 21 mutations
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
TWI812066B (zh)	2010-11-30	2023-08-11	日商中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
WO2012118547A1 (en)	2010-12-08	2012-09-07	Stem Centrx, Inc.	Novel modulators and methods of use
WO2012083370A1 (en)	2010-12-22	2012-06-28	Cephalon Australia Pty Ltd	Modified antibody with improved half-life
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
KR101276801B1 (ko)	2011-01-21	2013-06-19	한화엘앤씨 주식회사	ｓＴＮＦＲ1-Ｆｃ 유전자를 발현하는 형질전환 돼지 및 이의 용도
US9540443B2 (en)	2011-01-26	2017-01-10	Kolltan Pharmaceuticals, Inc.	Anti-kit antibodies
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
CN112812184A (zh)	2011-02-25	2021-05-18	中外制药株式会社	FcγRIIb特异性Fc抗体
US20130344074A1 (en)	2011-03-16	2013-12-26	Sanofi	Uses of a dual v region antibody-like protein
CA2830065A1 (en)	2011-03-16	2012-09-20	Amgen Inc.	Potent and selective inhibitors of nav1.3 and nav1.7
SG10201602394QA (en)	2011-03-29	2016-05-30	Roche Glycart Ag	Antibody FC Variants
RS55609B1 (sr)	2011-04-13	2017-06-30	Bristol Myers Squibb Co	Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
WO2015067913A1 (en)	2013-11-07	2015-05-14	Diagnodus Limited	Biomarkers
CA2836873C (en)	2011-05-21	2019-10-22	Macrogenics, Inc.	Deimmunized serum-binding domains and their use for extending serum half-life
US9328170B2 (en)	2011-05-25	2016-05-03	Merck Sharp & Dohme Corp.	Method for preparing Fc containing polypeptides having improved properties
UA113626C2 (xx)	2011-06-02	2017-02-27		Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
SG195253A1 (en)	2011-06-03	2013-12-30	Xoma Technology Ltd	Antibodies specific for tgf-beta
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
PE20240686A1 (es)	2011-06-10	2024-04-10	Hanmi Science Co Ltd	Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
PE20230404A1 (es)	2011-06-17	2023-03-07	Hanmi Science Co Ltd	Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
UA114478C2 (uk)	2011-06-28	2017-06-26	Берлін-Хемі Аг	Антитіло, яке специфічно зв'язується з bst1
CN109517059B (zh)	2011-06-30	2023-03-28	中外制药株式会社	异源二聚化多肽
KR20140053991A (ko)	2011-07-18	2014-05-08	아츠 바이올로직스 에이/에스	장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물
GB201112429D0 (en)	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
BR112014005091A2 (pt)	2011-09-05	2017-06-13	Beijing Hanmi Pharmaceutical Co Ltd	composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
UY34346A (es)	2011-09-26	2013-04-30	Novartis Ag	Proteínas de fusión para tratar trastornos metabólicos
TW201315742A (zh)	2011-09-26	2013-04-16	Novartis Ag	治療代謝病症之雙功能蛋白質
EP3680251A1 (en)	2011-09-30	2020-07-15	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecules for promoting elimination of antigens
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
ES2925654T3 (es)	2011-09-30	2022-10-19	Dana Farber Cancer Inst Inc	Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
TW201817744A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
EP2773664A1 (en)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49 antibodies
WO2013067054A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Antibodies and methods of treating cancer
AU2012332588B2 (en)	2011-11-01	2017-09-07	Bionomics, Inc.	Methods of blocking cancer stem cell growth
CA2854233C (en)	2011-11-04	2020-05-12	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the fc domain
CN104039830A (zh)	2011-11-04	2014-09-10	诺华股份有限公司	低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
AU2012335496B2 (en)	2011-11-11	2017-05-11	Ucb Biopharma Sprl	Albumin binding antibodies and binding fragments thereof
MY168297A (en)	2011-11-17	2018-10-23	Pfizer	Cytotoxic Peptides and Antibody Drug Conjugates Thereof
JP6124800B2 (ja)	2011-11-30	2017-05-10	中外製薬株式会社	免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
AU2012349735B2 (en)	2011-12-05	2016-05-19	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140103135A (ko)	2011-12-05	2014-08-25	노파르티스 아게	Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
US20150017157A1 (en)	2011-12-19	2015-01-15	Xoma (Us) Llc	Methods for treating acne
PE20150159A1 (es)	2011-12-21	2015-02-08	Novartis Ag	Composiciones y metodos para anticuerpos que actuan sobre el factor p
JP2015502397A (ja)	2011-12-23	2015-01-22	ファイザー・インク	部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
KR101895047B1 (ko)	2011-12-30	2018-09-06	한미사이언스 주식회사	면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
US10774132B2 (en)	2012-01-09	2020-09-15	The Scripps Research Instittue	Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en)	2012-01-09	2020-06-10	The Scripps Research Institute	Humanized antibodies with ultralong cdr3s
JP6226752B2 (ja)	2012-02-09	2017-11-08	中外製薬株式会社	抗体のＦｃ領域改変体
SG10201805584YA (en)	2012-02-24	2018-08-30	Chugai Pharmaceutical Co Ltd	ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
PE20190658A1 (es)	2012-02-24	2019-05-08	Abbvie Stemcentrx Llc	Moduladores y metodos de empleo novedosos
SI2834241T1 (sl)	2012-03-05	2021-06-30	Gilead Calistoga Llc	Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko)	2012-03-09	2016-10-11	한미사이언스 주식회사	비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
US10064951B2 (en)	2012-03-30	2018-09-04	Hanmi Science Co., Ltd.	Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2013169693A1 (en)	2012-05-09	2013-11-14	Bristol-Myers Squibb Company	Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
WO2013166594A1 (en)	2012-05-10	2013-11-14	Zymeworks Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
GB201208370D0 (en) *	2012-05-14	2012-06-27	Ucb Pharma Sa	Antibodies
KR102557309B1 (ko)	2012-05-15	2023-07-20	씨젠 인크.	자가-안정화 링커 접합체
EP3605090A1 (en) *	2012-05-23	2020-02-05	F. Hoffmann-La Roche AG	Selection method for therapeutic agents
EP2857419B1 (en)	2012-05-30	2021-01-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for eliminating aggregated antigens
EP3795215A1 (en)	2012-05-30	2021-03-24	Chugai Seiyaku Kabushiki Kaisha	Target tissue-specific antigen-binding molecule
WO2014004586A1 (en)	2012-06-25	2014-01-03	Zymeworks Inc.	Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US20140004121A1 (en)	2012-06-27	2014-01-02	Amgen Inc.	Anti-mesothelin binding proteins
LT3495387T (lt)	2012-07-13	2021-11-25	Roche Glycart Ag	Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
US20150166630A1 (en)	2012-07-19	2015-06-18	Amgen Inc.	Btnl3 proteins, nucleic acids, and antibodies and uses thereof
AR091902A1 (es)	2012-07-25	2015-03-11	Hanmi Pharm Ind Co Ltd	Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es)	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
CN116574185A (zh)	2012-07-25	2023-08-11	塞尔德克斯医疗公司	抗kit抗体及其用途
TW202237660A (zh)	2012-08-24	2022-10-01	日商中外製藥股份有限公司	FcγRIIb特異性Fc區域變異體
WO2014059028A1 (en)	2012-10-09	2014-04-17	Igenica, Inc.	Anti-c16orf54 antibodies and methods of use thereof
MX340090B (es)	2012-11-05	2016-06-23	Pfizer	Analogos de spliceostatina.
PE20151421A1 (es)	2012-11-06	2015-09-24	Hanmi Pharm Ind Co Ltd	Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
HK1214282A1 (zh)	2012-11-07	2016-07-22	辉瑞公司	抗-notch3抗体及抗体-药物缀合物
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9914785B2 (en)	2012-11-28	2018-03-13	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
WO2014089177A2 (en)	2012-12-04	2014-06-12	Massachusetts Institute Of Technology	Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
HUE053669T2 (hu)	2012-12-05	2021-07-28	Novartis Ag	Készítmények és eljárások EPO-t célzó antitestekre
CA2898262A1 (en)	2013-01-24	2014-07-31	Glaxosmithkline Intellectual Property Development Limited	Tnf-alpha antigen-binding proteins
KR102073748B1 (ko)	2013-01-31	2020-02-05	한미약품 주식회사	재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
ES2870802T3 (es)	2013-02-12	2021-10-27	Bristol Myers Squibb Co	Métodos de replegado de proteínas a elevado pH
EP3744728A1 (en)	2013-02-12	2020-12-02	Bristol-Myers Squibb Company	Tangential flow filtration based protein refolding methods
WO2014129895A1 (en)	2013-02-19	2014-08-28	Stichting Vu-Vumc	Means and method for increasing the sensitivity of cancers for radiotherapy
BR112015019909A2 (pt)	2013-02-22	2017-08-29	Abbvie Stemcentrx Llc	Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
TWI708782B (zh)	2013-02-26	2020-11-01	南韓商韓美藥品股份有限公司	新穎胰島素類似物及其用途
TR201910929T4 (tr)	2013-02-26	2019-08-21	Hanmi Pharm Ind Co Ltd	Bölgeye özel insülin konjugatı.
WO2014137161A1 (ko)	2013-03-05	2014-09-12	한미약품 주식회사	생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CA2902727C (en)	2013-03-06	2020-08-18	Protalix Ltd.	Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
US20160017020A1 (en)	2013-03-06	2016-01-21	Protalix Ltd.	Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
US10344060B2 (en)	2013-03-12	2019-07-09	Amgen Inc.	Potent and selective inhibitors of Nav1.7
JP6676521B2 (ja)	2013-03-14	2020-04-08	マクロジェニクス，インコーポレーテッド	二重特異性分子、薬学的組成物及びそれらの使用
US20160184458A1 (en)	2013-03-14	2016-06-30	Shire Human Genetic Therapies, Inc.	Mrna therapeutic compositions and use to treat diseases and disorders
EP2970479B1 (en)	2013-03-14	2019-04-24	Novartis AG	Antibodies against notch 3
EP2970488A2 (en)	2013-03-15	2016-01-20	AbbVie Biotechnology Ltd	Anti-cd25 antibodies and their uses
PL2968440T3 (pl)	2013-03-15	2019-12-31	Zymeworks Inc.	Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
KR20150130462A (ko)	2013-03-15	2015-11-23	다나-파버 캔서 인스티튜트 인크.	치료 펩티드
MX2015012563A (es)	2013-03-15	2016-10-26	Abbvie Biotechnology Ltd	Anticuerpos anti-cd25 y sus usos.
ES2699599T3 (es)	2013-03-15	2019-02-11	Abbvie Biotherapeutics Inc	Variantes de Fc
ES2768648T3 (es)	2013-03-29	2020-06-23	Alexion Pharma Inc	Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
AU2014250434B2 (en)	2013-04-02	2019-08-08	Chugai Seiyaku Kabushiki Kaisha	Fc region variant
KR20210094669A (ko)	2013-04-29	2021-07-29	에프. 호프만-라 로슈 아게	인간 fcrn-결합 변형된 항체 및 사용 방법
RU2687043C2 (ru)	2013-04-29	2019-05-06	Ф. Хоффманн-Ля Рош Аг	МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR101895634B1 (ko)	2013-05-31	2018-09-05	한미약품 주식회사	변이된 힌지 영역을 포함하는 IgG4 Fc 단편
SG11201509982UA (2)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
WO2014200349A1 (en)	2013-06-13	2014-12-18	Fast Forward Pharmaceutical B.V.	Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096891A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es)	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en)	2013-07-18	2019-04-18	Taurus Biosciences, Llc	Humanized antibodies with ultralong complementarity determining regions
CN105705167A (zh)	2013-07-25	2016-06-22	诺华股份有限公司	合成的apelin多肽的生物缀合物
MX2016001020A (es)	2013-07-25	2016-08-03	Novartis Ag	Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
CA2919477A1 (en)	2013-07-31	2015-02-05	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
KR102313341B1 (ko)	2013-08-26	2021-10-18	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
AU2014312310A1 (en)	2013-08-28	2016-04-07	Abbvie Stemcentrx Llc	Novel SEZ6 modulators and methods of use
AU2014312215B2 (en)	2013-08-28	2020-02-27	Abbvie Stemcentrx Llc	Site-specific antibody conjugation methods and compositions
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
TW201605468A (zh)	2013-09-27	2016-02-16	韓美藥品股份有限公司	長效人類生長激素接合物之製劑
ES2826398T3 (es)	2013-10-15	2021-05-18	Seagen Inc	Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
EP3057605A1 (en)	2013-10-18	2016-08-24	Novartis AG	Methods of treating diabetes and related disorders
PE20160870A1 (es)	2013-11-06	2016-09-09	Abbvie Stemcentrx Llc	Anticuerpos anti-claudina novedosos y metodos de uso
HRP20250551T1 (hr)	2013-11-27	2025-06-20	Zymeworks Bc Inc.	Bispecifični antigen-vezujući konstrukti koji ciljaju her2
EA201691078A1 (ru)	2013-12-06	2017-01-30	Дана-Фарбер Кэнсер Инститьют, Инк.	Терапевтические пептиды
TWI846009B (zh)	2013-12-19	2024-06-21	美商思進公司	與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
US9708327B2 (en)	2013-12-20	2017-07-18	Gilead Calistoga Llc	Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
WO2015095601A1 (en)	2013-12-20	2015-06-25	Gilead Calistoga Llc	Process methods for phosphatidylinositol 3-kinase inhibitors
CN112142843B (zh)	2013-12-24	2024-10-18	阿尔金克斯有限公司	FcRn拮抗剂及使用方法
RU2729194C2 (ru)	2013-12-27	2020-08-05	Займворкс Инк.	Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
RU2698969C2 (ru)	2014-01-15	2019-09-02	Ф.Хоффманн-Ля Рош Аг	Варианты fc-области с улучшенной способностью связываться с белком а
RU2727639C2 (ru) *	2014-01-15	2020-07-22	Ф.Хоффманн-Ля Рош Аг	Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
EP3098235A4 (en)	2014-01-20	2017-10-18	Hanmi Pharm. Co., Ltd.	Long-acting insulin and use thereof
PT3097122T (pt)	2014-01-24	2020-07-21	Ngm Biopharmaceuticals Inc	Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
CN106459055B (zh)	2014-01-27	2019-11-01	辉瑞大药厂	双功能细胞毒类药剂
SG10202001468UA (en)	2014-02-17	2020-04-29	Seattle Genetics Inc	Hydrophilic antibody-drug conjugates
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
WO2015139020A2 (en)	2014-03-14	2015-09-17	Dana-Farber Cancer Institute, Inc.	Vaccine compositions and methods for restoring nkg2d pathway function against cancers
AU2015242657B2 (en)	2014-03-31	2020-05-21	Hanmi Pharm. Co., Ltd.	Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
CA2944649C (en)	2014-04-04	2022-06-21	Bionomics, Inc.	Humanized antibodies that bind lgr5
CA2947605A1 (en)	2014-05-13	2015-11-19	Bioatla, Llc	Conditionally active biological proteins
EP3142700B1 (en)	2014-05-16	2021-03-03	Medimmune, LLC	Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
SG10201912986PA (en)	2014-05-28	2020-02-27	Agenus Inc	Anti-gitr antibodies and methods of use thereof
AR100639A1 (es)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh)	2014-05-30	2020-02-11	南韓商韓美藥品股份有限公司	包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
DK3154583T3 (da)	2014-06-04	2021-03-22	Biontech Res And Development Inc	Humane monoklonale antistoffer mod gangliosid gd2
KR20150140177A (ko)	2014-06-05	2015-12-15	한미약품 주식회사	단백질 및 펩타이드의 면역원성을 감소시키는 방법
PT3151921T (pt)	2014-06-06	2019-11-21	Bristol Myers Squibb Co	Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
JP6803236B2 (ja)	2014-06-10	2020-12-23	アムジェンインコーポレイテッド	アペリンポリペプチド
EP3154960A1 (en)	2014-06-13	2017-04-19	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors
EP3157942B1 (en)	2014-06-23	2020-06-17	Novartis AG	Site specific protein modifications
CA3151221C (en)	2014-06-30	2026-01-13	Altor Bioscience Corporation	Il-15-based molecules and methods of use thereof
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
WO2016020880A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
UA123624C2 (uk)	2014-09-03	2021-05-05	Бьорінґер Інґельхайм Інтернаціональ Ґмбх	Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
WO2016036916A1 (en)	2014-09-03	2016-03-10	Bioatla, Llc	Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
TW201617368A (zh)	2014-09-05	2016-05-16	史坦森特瑞斯公司	新穎抗ｍｆｉ２抗體及使用方法
WO2016044224A1 (en)	2014-09-15	2016-03-24	Amgen Inc.	Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
AU2015318556C1 (en)	2014-09-17	2021-01-07	Zymeworks Bc Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3201227A4 (en)	2014-09-29	2018-04-18	Duke University	Bispecific molecules comprising an hiv-1 envelope targeting arm
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6668345B2 (ja)	2014-11-21	2020-03-18	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	修飾された重鎖定常領域を含む抗体
MY189836A (en)	2014-11-21	2022-03-11	Bristol Myers Squibb Co	Antibodies against cd73 and uses thereof
GB201421901D0 (en)	2014-12-09	2015-01-21	Cambridge Entpr Ltd	A method of rational antibody design
PL3333191T3 (pl)	2014-12-11	2021-05-04	Pierre Fabre Médicament	Przeciwciała przeciwko c10orf54 i ich zastosowania
US20160168237A1 (en)	2014-12-12	2016-06-16	Alexion Pharmaceuticals, Inc.	Method for treating a complement mediated disorder caused by an infectious agent in a patient
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
KR101860280B1 (ko)	2014-12-19	2018-05-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
JP7211703B2 (ja)	2014-12-22	2023-01-24	ザロックフェラーユニバーシティー	抗ｍｅｒｔｋアゴニスト抗体及びその使用
CN107207594B (zh)	2014-12-23	2019-05-07	百时美施贵宝公司	针对tigit的抗体
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
MY185334A (en)	2014-12-30	2021-05-06	Hanmi Pharm Ind Co Ltd	Glucagon derivatives with improved stability
EP3244926B8 (en)	2015-01-14	2024-08-21	The Brigham and Women's Hospital, Inc.	Treatment of cancer with anti-lap monoclonal antibodies
CN107428818A (zh)	2015-01-29	2017-12-01	密西根州立大学校董会	隐藏多肽及其用途
CN114773470A (zh)	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US10894089B2 (en)	2015-02-17	2021-01-19	Hanmi Pharm. Co., Ltd.	Long-acting insulin or insulin analogue conjugate
AU2016222830B2 (en)	2015-02-24	2021-02-25	Bioatla Llc	Conditionally active biological proteins
US10711067B2 (en)	2015-03-03	2020-07-14	Xoma (Us) Llc	Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
MX2017011194A (es)	2015-03-03	2018-04-10	Kymab Ltd	Anticuerpos, usos y métodos.
US10870706B2 (en)	2015-03-20	2020-12-22	Pfizer Inc.	Bifunctional cytotoxic agents containing the CTI pharmacophore
TN2019000101A1 (en)	2015-05-29	2020-07-15	Bristol Myers Squibb Co	Antibodies against ox40 and uses thereof.
CA2982237A1 (en)	2015-06-05	2016-12-08	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
UY36751A (es)	2015-06-26	2017-01-31	Novartis Ag	Anticuerpos de factor xi y métodos de uso
AU2016285920A1 (en)	2015-06-29	2018-02-01	Bristol-Myers Squibb Company	Antibodies to CD40 with enhanced agonist activity
EA201890058A1 (ru)	2015-06-30	2018-07-31	Ханми Фарм. Ко., Лтд.	Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
CA3185706C (en)	2015-08-03	2025-11-18	Novartis Ag	METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH FGF21
US10435457B2 (en)	2015-08-06	2019-10-08	President And Fellows Of Harvard College	Microbe-binding molecules and uses thereof
UY36870A (es)	2015-08-28	2017-03-31	Hanmi Pharm Ind Co Ltd	Análogos de insulina novedosos
CN114605548A (zh)	2015-09-01	2022-06-10	艾吉纳斯公司	抗-pd-1抗体及其使用方法
AU2016320748B2 (en)	2015-09-09	2019-05-02	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
JP6516925B2 (ja)	2015-09-09	2019-05-22	ノバルティスアーゲー	胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
JP6932700B2 (ja)	2015-09-15	2021-09-08	アムジエン・インコーポレーテツド	４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
WO2017052329A1 (en)	2015-09-24	2017-03-30	Hanmi Pharm. Co., Ltd.	Protein complex by use of a specific site of an immunoglobulin fragment for linkage
EA201890790A1 (ru)	2015-09-29	2018-10-31	Селджин Корпорейшн	Связывающие pd-1 белки и способы их применения
CA2997444A1 (en)	2015-09-29	2017-04-06	Amgen Inc.	Asgr inhibitors for reducing cholesterol levels
WO2017059371A1 (en)	2015-10-01	2017-04-06	Amgen Inc.	Treatment of bile acid disorders
US11851488B2 (en)	2015-11-03	2023-12-26	Ambrx, Inc.	Anti-CD3-folate conjugates and their uses
JP6486316B2 (ja)	2015-11-03	2019-03-20	財團法人工業技術研究院ＩｎｄｕｓｔｒｉａｌＴｅｃｈｎｏｌｏｇｙＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
BR112018010172A2 (pt)	2015-11-19	2018-11-21	Bristol Myers Squibb Co	anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
EP3383910A1 (en)	2015-11-30	2018-10-10	AbbVie Inc.	ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
AU2016365114A1 (en)	2015-11-30	2018-05-17	Abbvie Biotherapeutics Inc.	Anti-huLRRC15 antibody drug conjugates and methods for their use
IL299072A (en)	2015-12-02	2023-02-01	Memorial Sloan Kettering Cancer Center	Antibodies and methods for using them
UY37003A (es)	2015-12-04	2017-06-30	Novartis Ag	Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
WO2017096262A1 (en)	2015-12-04	2017-06-08	Jomoco, Corp.	Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN108367043A (zh)	2015-12-04	2018-08-03	西雅图基因公司	季铵化的微管溶素化合物的缀合物
US10822408B2 (en)	2015-12-15	2020-11-03	Amgen Inc.	PACAP antibodies and uses thereof
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
EP3389711A1 (en)	2015-12-18	2018-10-24	Novartis AG	Antibodies targeting cd32b and methods of use thereof
US11359009B2 (en)	2015-12-25	2022-06-14	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
WO2017116204A1 (ko)	2015-12-31	2017-07-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
CN116003593A (zh)	2016-01-11	2023-04-25	苏黎世大学	针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
WO2017125897A1 (en)	2016-01-21	2017-07-27	Novartis Ag	Multispecific molecules targeting cll-1
AR107483A1 (es)	2016-01-29	2018-05-02	Hanmi Pharm Ind Co Ltd	Conjugado de enzimas terapéuticas
WO2017134547A1 (en)	2016-02-01	2017-08-10	Pfizer Inc.	Tubulysin analogs and methods for their preparation
ES2985566T3 (es)	2016-03-04	2024-11-06	Univ Rockefeller	Anticuerpos contra CD40 con actividad agonista mejorada
KR20230038311A (ko)	2016-03-04	2023-03-17	브리스톨-마이어스 스큅 컴퍼니	항-cd73 항체와의 조합 요법
JP6937773B2 (ja)	2016-03-07	2021-09-22	ハンミファーマシューティカルカンパニーリミテッド	ポリエチレングリコール誘導体及びその用途
CN108884142A (zh)	2016-03-16	2018-11-23	梅里麦克制药股份有限公司	用于癌症治疗的工程化trail
EP3432925A4 (en)	2016-03-22	2019-11-06	Bionomics Limited	ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
KR20180134351A (ko)	2016-03-25	2018-12-18	시애틀 지네틱스, 인크.	페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
JP2019513371A (ja)	2016-04-01	2019-05-30	アビディティーバイオサイエンシーズエルエルシー	核酸ポリペプチド組成物とその使用
JP6967528B2 (ja)	2016-04-04	2021-11-17	バイオベラティブユーエスエーインコーポレイテッド	抗補体Ｂｂ因子抗体及びその使用
TWI781098B (zh)	2016-04-15	2022-10-21	美商宏觀基因股份有限公司	新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
EP3454864A4 (en)	2016-04-21	2021-01-13	Abbvie Stemcentrx LLC	Novel anti-bmpr1b antibodies and methods of use
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
AU2017271593B2 (en) *	2016-05-27	2021-04-22	Altor Bioscience Corporation	Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
TWI781934B (zh)	2016-05-27	2022-11-01	美商艾吉納斯公司	抗-tim-3抗體及其使用方法
JP2019517473A (ja)	2016-05-27	2019-06-24	アレクシオンファーマシューティカルズインコーポレイテッドＡｌｅｘｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	難治性全身型重症筋無力症の処置のための方法
EP3468997B1 (en)	2016-06-08	2023-09-13	Xencor, Inc.	Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
EP3471759A1 (en)	2016-06-15	2019-04-24	Novartis AG	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
BR112018076247A2 (pt)	2016-06-16	2019-03-26	The Board Of Trustees Of The Leland Stanford Junior University	anticorpos monoclonais quiméricos e humanizados para cd81
CA3029209A1 (en)	2016-06-21	2017-12-28	Teneobio, Inc.	Cd3 binding antibodies
KR102005457B1 (ko)	2016-06-29	2019-07-30	한미약품 주식회사	글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
AU2017292184A1 (en)	2016-07-08	2019-02-07	Staten Biotechnology B.V.	Anti-Apoc3 antibodies and methods of use thereof
MY200602A (en)	2016-07-14	2024-01-04	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
SG11201900616UA (en)	2016-08-02	2019-02-27	Visterra Inc	Engineered polypeptides and uses thereof
WO2018025168A1 (en)	2016-08-03	2018-02-08	Pfizer Inc.	Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
TWI693940B (zh)	2016-08-05	2020-05-21	日商中外製藥股份有限公司	Ｉｌ-８相關疾病之治療用或預防用組成物
MX2019001302A (es)	2016-08-09	2019-06-12	Seattle Genetics Inc	Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
WO2018044970A1 (en)	2016-08-31	2018-03-08	University Of Rochester	Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
FI4050034T3 (fi)	2016-09-14	2024-06-10	Teneoone Inc	Cd3:een sitoutuvia vasta-aineita
EP3515943A4 (en)	2016-09-19	2020-05-06	Celgene Corporation	METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
BR112019004733A2 (pt)	2016-09-19	2019-05-28	Celgene Corp	métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
RU2764197C1 (ru)	2016-09-23	2022-01-14	Ханми Фарм. Ко., Лтд.	Аналоги инсулина с пониженной аффинностью к рецептору инсулина и их применение
SG10201912663YA (en)	2016-10-11	2020-03-30	Agenus Inc	Anti-lag-3 antibodies and methods of use thereof
TWI835714B (zh)	2016-10-18	2024-03-21	美商思進公司	菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
JP7096240B2 (ja)	2016-10-19	2022-07-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	試料中の非結合ｃ５の定量化方法
CN118562016A (zh)	2016-10-21	2024-08-30	艾尔特生物科技公司	基于多聚体il-15的分子
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr)	2016-11-09	2019-09-18	Agenus Inc	Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3538555A1 (en)	2016-11-14	2019-09-18	Amgen Inc.	Bispecific or biparatopic antigen binding proteins and uses thereof
US20230192896A1 (en)	2016-11-23	2023-06-22	Bioverativ Therapeutics Inc.	Bispecific antibodies binding to coagulation factor ix and coagulation factor x
CN110291103A (zh)	2016-12-05	2019-09-27	韩美药品株式会社	具有弱化的免疫应答的缀合物
WO2018104893A1 (en)	2016-12-06	2018-06-14	Glaxosmithkline Intellectual Property Development Limited	Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
WO2018106862A1 (en)	2016-12-07	2018-06-14	Agenus Inc.	Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (ja)	2016-12-07	2022-07-26	アジェナスインコーポレイテッド	抗体およびその使用方法
US20190352335A1 (en)	2016-12-19	2019-11-21	Hanmi Pharm. Co., Ltd.	Brain targeting long-acting protein conjugate
NZ754713A (en)	2016-12-21	2025-11-28	Teneobio Inc	Anti-bcma heavy chain-only antibodies
IL267538B2 (en)	2016-12-23	2024-05-01	Novartis Ag	Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110325211A (zh)	2016-12-23	2019-10-11	诺华股份有限公司	采用抗因子XI/XIa抗体治疗的方法
MX2019008199A (es)	2017-01-06	2019-11-25	Avidity Biosciences Llc	Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
WO2018129451A2 (en)	2017-01-09	2018-07-12	Merrimack Pharmaceuticals, Inc.	Anti-fgfr antibodies and methods of use
MX2019008773A (es)	2017-01-24	2019-09-18	Pfizer	Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
JP2020506932A (ja)	2017-02-03	2020-03-05	ハンミファーマシューティカルカンパニーリミテッド	持続性が増加した生理活性物質の結合体及びその用途
CN110545852B (zh)	2017-02-07	2023-05-26	韩美药品株式会社	非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
US10899844B2 (en)	2017-02-08	2021-01-26	Novartis Ag	FGF21 mimetic antibodies and uses thereof
CN110506057B (zh)	2017-02-17	2023-09-29	百时美施贵宝公司	Alpha突触核蛋白抗体及其应用
CN117986384A (zh)	2017-03-06	2024-05-07	艾尔特生物科技公司	与il-12和il-18的基于il-15的融合物
KR101941975B1 (ko)	2017-03-17	2019-01-25	고려대학교 산학협력단	Atpif1을 함유하는 당뇨 치료용 약학조성물
AR111341A1 (es)	2017-03-23	2019-07-03	Hanmi Pharm Ind Co Ltd	Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
AU2018237683A1 (en)	2017-03-24	2019-10-31	Seagen Inc.	Process for the preparation of glucuronide drug-linkers and intermediates thereof
US20190048055A1 (en)	2017-03-31	2019-02-14	Altor Bioscience Corporation	Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN110505885A (zh)	2017-04-05	2019-11-26	诺和诺德股份有限公司	寡聚体延伸的胰岛素-Fc缀合物
US11634495B2 (en)	2017-04-07	2023-04-25	Miltenyi Biotec B.V. & Co. KG	Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
JP7297672B2 (ja)	2017-04-13	2023-06-26	アジェナスインコーポレイテッド	抗ｃｄ１３７抗体およびその使用方法
JOP20190248A1 (ar)	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
JP2020517242A (ja) *	2017-04-21	2020-06-18	スターテン・バイオテクノロジー・ベー・フェー	抗ＡｐｏＣ３抗体およびその使用方法
US11643473B2 (en)	2017-04-24	2023-05-09	Alexion Pharmaceuticals, Inc.	Antibody immune cell inhibitor fusion proteins
WO2018201087A1 (en)	2017-04-27	2018-11-01	Seattle Genetics, Inc.	Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
RS64576B1 (sr)	2017-05-01	2023-10-31	Agenus Inc	Anti-tigit antitela i postupci njihove primene
EP3625251A1 (en)	2017-05-15	2020-03-25	University Of Rochester	Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
EP3630162A1 (en)	2017-05-24	2020-04-08	Novartis AG	Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en)	2017-05-24	2018-11-29	Novartis Ag	Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
BR112019024556A2 (pt)	2017-05-24	2020-06-23	Novartis Ag	Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
JOP20190271A1 (ar)	2017-05-24	2019-11-21	Novartis Ag	بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
IL270596B2 (en)	2017-05-25	2026-01-01	Bristol Myers Squibb Co	Antibodies containing heavy constant regions are adapted for use in cancer therapy
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
IL271194B2 (en)	2017-06-20	2024-10-01	Teneobio Inc	Anti-bcma heavy chain-only antibodies
US11427642B2 (en)	2017-06-20	2022-08-30	Teneoone, Inc.	Anti-BCMA heavy chain-only antibodies
SG11202000115SA (en)	2017-07-07	2020-02-27	Hanmi Pharmaceutical Co Ltd	Novel therapeutic enzyme fusion protein and use thereof
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
SI3658184T1 (sl)	2017-07-27	2024-01-31	Alexion Pharmaceuticals, Inc.,	Formulacije z visoko koncentracijo protiteles proti-C5
EP3672990A1 (en)	2017-08-25	2020-07-01	Five Prime Therapeutics, Inc.	B7-h4 antibodies and methods of use thereof
EP3676289B1 (en)	2017-08-28	2026-03-04	Altor BioScience, LLC	Il-15-based fusions to il-7 and il-21
KR20200044094A (ko)	2017-09-13	2020-04-28	테네오바이오, 인코포레이티드	엑토효소에 결합하는 중쇄 항체
CA3084326A1 (en)	2017-09-28	2019-04-04	Jaehyuk Choi	Long-acting conjugates of glp-2 derivatives
KR20190036956A (ko)	2017-09-28	2019-04-05	한미약품 주식회사	지속형 단쇄 인슐린 아날로그 및 이의 결합체
US11357861B2 (en)	2017-09-29	2022-06-14	Hanmi Pharm. Co., Ltd	Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
WO2019066603A1 (ko)	2017-09-29	2019-04-04	한미약품 주식회사	효력이 향상된 지속성 단백질 결합체
WO2019071028A1 (en)	2017-10-04	2019-04-11	Avidity Biosciences Llc	NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
US11707522B2 (en)	2017-10-13	2023-07-25	Boehringer Ingelheim International Gmbh	Human antibodies to Tn antigen
EP3700933A1 (en)	2017-10-25	2020-09-02	Novartis AG	Antibodies targeting cd32b and methods of use thereof
CA3080187A1 (en)	2017-10-26	2019-05-02	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
KR20200074975A (ko)	2017-10-31	2020-06-25	스태튼 바이오테크놀로지 비.브이.	항-ApoC3 항체 및 이의 사용 방법
US10538583B2 (en)	2017-10-31	2020-01-21	Staten Biotechnology B.V.	Anti-APOC3 antibodies and compositions thereof
EP3710589A4 (en)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	ANTI-C1S ANTIBODIES AND METHOD OF USING
JP7506601B2 (ja)	2017-12-06	2024-06-26	アビディティーバイオサイエンシーズ，インク．	筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
US12240875B2 (en)	2017-12-08	2025-03-04	argenx BV	Use of FCRN antagonists for treatment of generalized myasthenia gravis
MX2020006635A (es)	2017-12-22	2020-12-10	Hanmi Pharm Ind Co Ltd	Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
US20200376080A1 (en)	2017-12-22	2020-12-03	Novartis Ag	Methods of treating metabolic disorders with fgf21 variants
WO2019126756A1 (en)	2017-12-22	2019-06-27	Teneobio, Inc.	Heavy chain antibodies binding to cd22
CN111788227B (zh)	2017-12-27	2025-02-25	百时美施贵宝公司	抗cd40抗体及其用途
RU2020124623A (ru)	2017-12-27	2022-01-27	Тенеобио, Инк.	Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
KR20250078626A (ko)	2018-01-12	2025-06-02	브리스톨-마이어스 스큅 컴퍼니	Tim3에 대한 항체 및 그의 용도
UY38050A (es)	2018-01-12	2019-07-31	Amgen Inc	Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
CN111989339A (zh)	2018-02-20	2020-11-24	西雅图基因公司	疏水性奥瑞他汀f化合物及其缀合物
JP2021514379A (ja)	2018-02-21	2021-06-10	ファイブプライムセラピューティクス，インコーポレイテッド	Ｂ７−ｈ４抗体製剤
CN111787951B (zh) *	2018-03-01	2025-06-17	Igm生物科学股份有限公司	影响IgM血清半衰期的IgM Fc和J链突变
MA52416A (fr)	2018-03-02	2021-04-21	Five Prime Therapeutics Inc	Anticorps b7-h4 et leurs procédés d'utilisation
PE20210665A1 (es)	2018-03-23	2021-03-31	Bristol Myers Squibb Co	Anticuerpos contra mica y/o micb y sus usos
TW202003011A (zh)	2018-03-26	2020-01-16	美商艾爾特生物科技責任有限公司	抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
WO2019184909A1 (zh)	2018-03-27	2019-10-03	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
CN110305210B (zh)	2018-03-27	2023-02-28	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
KR20190114907A (ko)	2018-03-30	2019-10-10	한미약품 주식회사	뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
EP3774902A1 (en)	2018-04-02	2021-02-17	Bristol-Myers Squibb Company	Anti-trem-1 antibodies and uses thereof
CN110396133B (zh)	2018-04-25	2021-07-23	免疫靶向有限公司	一种以白介素12为活性成分的融合蛋白型药物前体
JP7485368B2 (ja)	2018-04-26	2024-05-16	グッドティーセルズ、インコーポレイテッド	新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
EP3787678A1 (en)	2018-05-03	2021-03-10	University Of Rochester	Anti-influenza neuraminidase monoclonal antibodies and uses thereof
MA52571A (fr)	2018-05-08	2021-03-17	Amgen Inc	Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US12404320B2 (en)	2018-05-31	2025-09-02	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
JP7577542B2 (ja)	2018-06-04	2024-11-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
TWI851577B (zh)	2018-06-07	2024-08-11	美商思進公司	喜樹鹼結合物
CA3101462A1 (en)	2018-06-08	2019-12-12	Argenx Bvba	Compositions and methods for treating immune thrombocytopenia
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
EP3806884B1 (en)	2018-06-15	2023-08-02	Amyl Therapeutics	General amyloid interaction motif (gaim)
JP7637415B2 (ja)	2018-06-22	2025-02-28	キュージーンインコーポレイテッド	インターロイキン－２バリアントおよびその使用方法
WO2020006266A1 (en)	2018-06-28	2020-01-02	Alexion Pharmaceuticals, Inc.	Methods of producing anti-c5 antibodies
KR102767692B1 (ko)	2018-07-20	2025-02-17	피에르 파브르 메디카먼트	Vista의 수용체
PL3823990T3 (pl)	2018-07-20	2026-04-20	TeneoTwo, Inc.	Przeciwciała łańcucha ciężkiego wiążące się z cd19
US20210347849A1 (en)	2018-07-24	2021-11-11	Good T Cells, Inc.	Composition for Preventing or Treating Immune-Related Diseases
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3835321A4 (en)	2018-08-10	2022-11-02	Chugai Seiyaku Kabushiki Kaisha	ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
WO2020037120A1 (en)	2018-08-16	2020-02-20	Nantbio, Inc.	Il7-il15 txm compositions and methods
CN112839959A (zh)	2018-09-21	2021-05-25	特尼奥生物股份有限公司	用于纯化异源二聚多特异性抗体的方法
CN110964116A (zh)	2018-09-26	2020-04-07	北京辅仁瑞辉生物医药研究院有限公司	GLP1-Fc融合蛋白及其缀合物
SG11202102851XA (en)	2018-09-27	2021-04-29	Celgene Corp	SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
WO2020070678A2 (en)	2018-10-03	2020-04-09	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
JP7684902B2 (ja)	2018-10-04	2025-05-28	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン及びこれを含む組合せ物の治療学的用途
CN112839681A (zh)	2018-10-10	2021-05-25	诺和诺德股份有限公司	寡聚体延伸的胰岛素-Fc缀合物及其医学用途
EP3863722A2 (en)	2018-10-10	2021-08-18	Tilos Theapeutics, Inc.	Anti-lap antibody variants and uses thereof
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
TWI824043B (zh)	2018-10-25	2023-12-01	西班牙商瑪製藥股份有限公司	藥物抗體共軛物
BR112021000173A2 (pt)	2018-10-26	2021-05-04	Teneobio, Inc.	anticorpos de cadeia pesada com ligação a cd38
EP3873519A1 (en)	2018-10-29	2021-09-08	F. Hoffmann-La Roche AG	Antibody formulation
CN112996561A (zh)	2018-10-30	2021-06-18	亚力兄制药公司	用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
US11274150B2 (en)	2018-11-16	2022-03-15	Bristol-Myers Squibb Company	Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
EP3887397A1 (en)	2018-11-28	2021-10-06	Bristol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
WO2020130749A1 (ko)	2018-12-21	2020-06-25	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
IL312067B2 (en)	2018-12-21	2025-08-01	Avidity Biosciences Inc	Anti-transferrin receptor antibodies and uses thereof
AU2019405389B2 (en)	2018-12-21	2025-06-05	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition containing insulin and glucagon
US11008395B2 (en)	2019-01-22	2021-05-18	Bristol Myers-Squibb Company	Antibodies against IL-7R alpha subunit and uses thereof
MA55080A (fr)	2019-02-26	2022-01-05	Inspirna Inc	Anticorps anti-mertk à affinité élevée et utilisations associées
JP7776987B2 (ja)	2019-04-05	2025-11-27	テネオバイオ，インコーポレイテッド	Ｐｓｍａに結合する重鎖抗体
KR102524577B1 (ko)	2019-04-22	2023-04-21	전남대학교산학협력단	플라젤린 융합 단백질 및 이의 용도
US12497615B2 (en)	2019-04-25	2025-12-16	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
US12134655B2 (en)	2019-04-30	2024-11-05	Absci Corporation	Cancer associated antibody compositions and methods of use
MX2021013657A (es)	2019-05-10	2022-02-21	Takeda Pharmaceuticals Co	Conjugados de anticuerpo y farmaco.
MX2021013441A (es)	2019-05-15	2021-12-10	Chugai Pharmaceutical Co Ltd	Molecula de union a antigenos, composicion farmaceutica y metodo.
PE20220568A1 (es)	2019-05-21	2022-04-20	Novartis Ag	Moleculas de union a cd19 y usos de las mismas
EP3972993A1 (en)	2019-05-21	2022-03-30	Novartis AG	Variant cd58 domains and uses thereof
WO2020242989A1 (en)	2019-05-24	2020-12-03	Sanofi	Methods for treating systemic sclerosis
JP7500619B2 (ja)	2019-05-30	2024-06-17	アムジエン・インコーポレーテツド	抗体の二量体化を促進するためのヒンジ領域の操作
KR20220019259A (ko)	2019-06-06	2022-02-16	어비디티 바이오사이언시스 인크.	Una 아미다이트 및 이의 용도
JP7592034B2 (ja)	2019-06-06	2024-11-29	アビディティーバイオサイエンシーズ，インク．	核酸ポリペプチド組成物およびその使用
CN114126647A (zh)	2019-06-07	2022-03-01	阿尔金克斯有限公司	适用于皮下施用的FcRn抑制剂的药物制剂
CN114206927B (zh)	2019-06-14	2025-03-21	特尼奥生物股份有限公司	与cd22和cd3结合的多特异性重链抗体
AU2020304671A1 (en)	2019-06-28	2022-01-20	Amgen Inc.	Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
DK3936142T3 (da)	2019-06-28	2024-03-25	Hanmi Pharmaceutical Co Ltd	Tredobbelt agonist med aktivitet med hensyn til alle glucagon-, GLP-1- og GLP-receptorer til behandling af leversygdom
CN114144435B (zh)	2019-07-15	2024-06-25	百时美施贵宝公司	针对人trem-1的抗体及其用途
JP7796005B2 (ja)	2019-07-15	2026-01-08	ブリストル－マイヤーズスクイブカンパニー	抗ｔｒｅｍ－１抗体およびその使用
US12558431B2 (en)	2019-07-18	2026-02-24	Hanmi Pharm. Co., Ltd.	Method of preparing protein conjugate
BR112022000760B1 (pt)	2019-07-18	2024-01-02	Hanmi Pharm. Co., Ltd	Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração
CN120842421A (zh)	2019-07-30	2025-10-28	魁尔斯弗生物治疗股份有限公司	双特异性抗LRRC15和CD3ε抗体
CN114867751B (zh)	2019-08-12	2024-11-29	阿帕特夫研究和发展有限公司	4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
TW202122420A (zh)	2019-08-30	2021-06-16	美商艾吉納斯公司	抗ｃｄ９６抗體及其使用方法
CN114615999B (zh)	2019-09-05	2024-03-08	法马马有限公司	药物抗体偶联物
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
AR120079A1 (es)	2019-09-19	2022-02-02	Seattle Genetics Inc	Liberación selectiva de fármacos de conjugados internalizados de compuestos biológicamente activos
AU2020356955A1 (en)	2019-10-04	2022-04-14	Seagen Inc.	Camptothecin peptide conjugates
WO2021067820A1 (en)	2019-10-04	2021-04-08	Seagen Inc.	Formulation of antibody-drug conjugate
WO2021066600A1 (ko)	2019-10-04	2021-04-08	한미약품 주식회사	글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
WO2021081440A2 (en)	2019-10-24	2021-04-29	Minotaur Therapeutics, Inc.	Chimeric cytokine modified antibodies and methods of use thereof
EP4628498A3 (en)	2019-11-08	2026-03-04	Amgen Inc.	Engineering charge pair mutations for pairing of hetero-igg molecules
EP4061838A1 (en)	2019-11-19	2022-09-28	Amgen Inc.	Novel multispecific antibody format
JP7807076B2 (ja)	2019-12-13	2026-01-27	キュージーンインコーポレイテッド	新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
WO2021127489A1 (en)	2019-12-18	2021-06-24	Teneobio, Inc.	Heavy chain antibodies binding to cd38
MX2022007688A (es)	2019-12-20	2022-07-19	Amgen Inc	Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
JP7846622B2 (ja)	2019-12-24	2026-04-15	ハンミファーマシューティカルカンパニーリミテッド	Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物
BR112022013554A2 (pt)	2020-01-08	2022-09-06	argenx BV	Métodos para tratar distúrbios do pênfigo
PE20221595A1 (es)	2020-01-13	2022-10-10	Hanmi Pharm Ind Co Ltd	Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares
MX2022010457A (es)	2020-02-25	2022-11-16	Mediboston Ltd	Derivados de camptotecina y conjugados de esta.
US11555190B2 (en)	2020-03-19	2023-01-17	Avidity Biosciences, Inc.	Compositions and methods of treating Facioscapulohumeral muscular dystrophy
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
FI4045533T3 (fi)	2020-03-26	2024-02-02	Univ Vanderbilt	Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
AU2021241682B2 (en)	2020-03-27	2026-02-12	Avidity Biosciences, Inc.	Compositions and methods of treating muscle dystrophy
WO2021195574A1 (en) *	2020-03-27	2021-09-30	Alnylam Pharmaceuticals, Inc.	Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20210121585A (ko)	2020-03-30	2021-10-08	한국세라믹기술원	반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
WO2021202235A1 (en)	2020-04-01	2021-10-07	University Of Rochester	Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
EP4144361A4 (en)	2020-04-03	2024-05-22	Hanmi Pharm. Co., Ltd.	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY OR A COMBINATION THEREOF, WITH GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE THEREOF
CN121577897A (zh) *	2020-04-08	2026-02-27	豪夫迈·罗氏有限公司	大分子非特异性清除测定
EP4132971A1 (en)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinity matured anti-lap antibodies and uses thereof
BR112022020531A2 (pt)	2020-04-20	2022-12-06	Hanmi Pharm Ind Co Ltd	Composição farmacêutica
KR20230004686A (ko)	2020-04-20	2023-01-06	젠자임 코포레이션	인간화 항-보체 인자 Bb 항체 및 그의 용도
KR20230004714A (ko)	2020-04-21	2023-01-06	파르마 마르, 에스.에이.	약물 항체 접합체
MX2021015024A (es)	2020-04-28	2022-01-18	Univ Rockefeller	Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
AU2021263448B2 (en)	2020-04-29	2026-02-05	Teneobio, Inc.	Multispecific heavy chain antibodies with modified heavy chain constant regions
CA3185805A1 (en)	2020-04-29	2021-11-04	Teneoone, Inc.	Methods of treating multiple myeloma
TWI838621B (zh)	2020-04-29	2024-04-11	美商泰尼歐萬公司	具有經修飾重鏈恆定區之多特異性重鏈抗體
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
AU2021275361A1 (en)	2020-05-17	2023-01-19	Astrazeneca Uk Limited	SARS-CoV-2 antibodies and methods of selecting and using the same
EP4154869A4 (en)	2020-05-22	2025-01-22	Hanmi Pharm. Co., Ltd.	Liquid formulation of long-acting conjugate of glp-2
BR112022023609A2 (pt)	2020-05-22	2023-02-07	Hanmi Pharm Ind Co Ltd	Formulação líquida de conjugado de ação prolongada de agonista trigonal de glucagon, glp-1 e gip
BR112022023618A2 (pt)	2020-05-22	2023-02-07	Hanmi Pharm Ind Co Ltd	Formulação líquida de conjugado de ação prolongada de derivado de glucagon
MX2022014670A (es)	2020-05-22	2023-02-13	Hanmi Pharm Ind Co Ltd	Formulacion liquida.
MX2022016548A (es)	2020-06-26	2023-03-14	Amgen Inc	Muteínas de il-10 y proteínas de fusión de las mismas.
IL299027A (en)	2020-06-30	2023-02-01	Teneobio Inc	Multispecific antibodies that bind BCMA
WO2022015082A1 (ko)	2020-07-15	2022-01-20	한미약품 주식회사	글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
JP7846667B2 (ja)	2020-07-16	2026-04-15	レジェンドバイオテックアイルランドリミテッド	Ｃｄ２０結合分子及びその使用
CA3186416A1 (en)	2020-07-17	2022-01-20	John A. Barrett	Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
BR112023000585A2 (pt)	2020-07-17	2023-03-28	Hanmi Pharm Ind Co Ltd	Composição farmacêutica e uso da mesma
EP4230216A4 (en)	2020-07-24	2025-02-19	Jiangsu Gensciences Inc.	Insulin-fc fusion protein and application thereof
EP4188960A4 (en)	2020-08-03	2024-09-11	Janssen Biotech, Inc.	MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
IL300376A (en)	2020-08-06	2023-04-01	Bioverativ Usa Inc	Inflammatory cytokines and fatigue in subjects with complement-mediated disease
AU2021325339A1 (en)	2020-08-10	2023-04-06	Astrazeneca Uk Limited	SARS-CoV-2 antibodies for treatment and prevention of COVID-19
MX2023001599A (es)	2020-08-14	2023-03-07	Hanmi Pharmaceutical Co Ltd	Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip.
EP4197550A4 (en)	2020-08-14	2025-10-08	Hanmi Pharmaceutical Co Ltd	PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS
MX2023002125A (es)	2020-08-20	2023-04-26	Amgen Inc	Proteínas de unión a antígenos con disulfuro no canónico en la región fab.
JP2023543036A (ja)	2020-09-25	2023-10-12	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途
CN116419766A (zh)	2020-09-25	2023-07-11	韩美药品株式会社	作用于胰高血糖素、glp-1和gip受体全部的三重激动剂的长效缀合物对抗多发性硬化的治疗用途
KR20220041765A (ko)	2020-09-25	2022-04-01	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
AU2021358033A1 (en)	2020-10-07	2023-05-04	Amgen Inc.	Rational selection of building blocks for the assembly of multispecific antibodies
WO2022080986A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
WO2022082005A1 (en)	2020-10-16	2022-04-21	Qlsf Biotherapeutics, Inc.	Multispecific binding compounds that bind to pd-l1
US20230381281A1 (en)	2020-10-16	2023-11-30	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
KR20220050824A (ko)	2020-10-16	2022-04-25	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
WO2022080987A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
WO2022080985A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	Gip 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
WO2022080984A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
TW202227481A (zh)	2020-11-04	2022-07-16	美國洛克菲勒大學	中和抗sars-cov-2抗體
US20240025993A1 (en)	2020-11-06	2024-01-25	Novartis Ag	Cd19 binding molecules and uses thereof
JP7397996B2 (ja)	2020-11-09	2023-12-13	武田薬品工業株式会社	抗体薬物コンジュゲート
WO2022103773A1 (en)	2020-11-10	2022-05-19	Amgen Inc.	Novel linkers of multispecific antigen binding domains
CN116419759A (zh)	2020-11-13	2023-07-11	韩美药品株式会社	治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途
JP2023549323A (ja)	2020-11-13	2023-11-24	ハンミファーマシューティカルカンパニーリミテッド	治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途
TW202233684A (zh)	2020-11-18	2022-09-01	美商泰尼歐生物公司	結合於葉酸受體α之重鏈抗體
US20240301086A1 (en)	2020-12-01	2024-09-12	Aptevo Research And Development Llc	Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
WO2022122654A1 (en)	2020-12-07	2022-06-16	UCB Biopharma SRL	Multi-specific antibodies and antibody combinations
WO2022131889A1 (ko)	2020-12-16	2022-06-23	주식회사 굳티셀	Taci 단백질의 용도
US20230382974A1 (en)	2020-12-24	2023-11-30	Hanmi Pharm. Co., Ltd.	Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use thereof
AU2021409610A1 (en)	2020-12-24	2023-07-06	Hanmi Pharm. Co., Ltd.	Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
US20240117356A1 (en)	2020-12-31	2024-04-11	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2024502832A (ja)	2020-12-31	2024-01-23	アラマーバイオサイエンシーズ，インコーポレイテッド	高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
JP2024505636A (ja)	2021-01-15	2024-02-07	ザロックフェラーユニバーシティー	抗ｓａｒｓ－ｃｏｖ－２中和抗体
JP2024505943A (ja)	2021-01-29	2024-02-08	ハンミファーマシューティカルズカンパニーリミテッド	Ｇｉｐ誘導体、またはその持続型結合体を含む肺疾患の予防用または治療用の薬学的組成物
CA3211138A1 (en)	2021-02-25	2022-09-01	Teneobio, Inc.	Anti-psma antibodies and car-t structures
US12521444B2 (en)	2021-02-25	2026-01-13	Fortvita Biologics Limited	Anti-HER2 antibody-drug conjugates and uses thereof
WO2022183101A1 (en)	2021-02-26	2022-09-01	Teneobio, Inc.	Anti-muc1-c antibodies and car-t structures
MX2023010819A (es)	2021-03-18	2023-09-28	Seagen Inc	Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
AU2022238571A1 (en)	2021-03-18	2023-09-14	Seagen Inc.	Selective drug release from internalized conjugates of biologically active compounds
IL304365B2 (en)	2021-03-31	2025-04-01	Hanmi Pharmaceutical Co Ltd	A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
CN117241828A (zh)	2021-03-31	2023-12-15	美国比奥维拉迪维股份有限公司	减少冷凝集素病患者的手术相关溶血
TW202304994A (zh)	2021-04-02	2023-02-01	美商泰尼歐生物公司	促效性抗ｉｌ－２ｒ抗體及使用方法
JP2024514530A (ja)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	切断型ｃｄｃｐ１に対する抗体およびその使用
PE20232050A1 (es)	2021-04-06	2023-12-27	Teneobio Inc	Anticuerpos anti-cd19 y estructuras car-t
EP4321170A4 (en)	2021-04-09	2025-07-16	Hanmi Pharmaceutical Co Ltd	PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC KIDNEY DISEASE CONTAINING A GLUCAGON DERIVATIVE
WO2022221698A1 (en)	2021-04-16	2022-10-20	Teneobio, Inc.	Anti-cd20 antibodies and car-t structures
JP2024515301A (ja)	2021-04-20	2024-04-08	アムジエン・インコーポレーテツド	多重特異性及び一価のｉｇｇ分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
WO2022232321A1 (en)	2021-04-28	2022-11-03	Minotaur Therapeutics, Inc.	Humanized chimeric bovine antibodies and methods of use
WO2022235867A2 (en)	2021-05-06	2022-11-10	The Rockefeller University	Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
JP2024522213A (ja)	2021-06-14	2024-06-11	アルジェニクスビーブイ	抗ｉｌ－９抗体及びその使用方法
WO2022271987A1 (en)	2021-06-23	2022-12-29	TeneoFour, Inc.	Anti-cd38 antibodies and epitopes of same
EP4359441A1 (en)	2021-06-25	2024-05-01	Amgen Inc.	Treatment of cardiovascular disease with trem-1 antigen binding proteins
KR20230004135A (ko)	2021-06-30	2023-01-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023004197A1 (en)	2021-07-23	2023-01-26	Teneoten, Inc.	Heavy chain antibodies binding to hepatitis b surface antigen
WO2023031615A1 (en)	2021-09-02	2023-03-09	Djs Antibodies Ltd	Polypeptides
MX2024003266A (es)	2021-09-16	2024-04-03	Avidity Biosciences Inc	Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
CN118541392A (zh)	2021-09-28	2024-08-23	准星生物医药有限公司	多种形式的分子复合物
IL311655A (en)	2021-09-30	2024-05-01	Seagen Inc	B7-H4 antibody-drug conjugates for cancer treatment
TW202323281A (zh)	2021-10-14	2023-06-16	美商泰尼歐生物公司	間皮素結合蛋白及其用途
TW202342095A (zh)	2021-11-05	2023-11-01	英商阿斯特捷利康英國股份有限公司	用於治療和預防ｃｏｖｉｄ—１９之組成物
JP2024540480A (ja)	2021-11-17	2024-10-31	ディスク・メディシン・インコーポレイテッド	腎臓疾患の貧血を処置する方法
KR20230095666A (ko)	2021-12-22	2023-06-29	한미약품 주식회사	간 표적 물질 및 이의 용도
KR20230095665A (ko)	2021-12-22	2023-06-29	한미약품 주식회사	간 표적 약물 및 이의 용도
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
EP4469159A1 (en)	2022-01-27	2024-12-04	The Rockefeller University	Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
WO2023173084A1 (en)	2022-03-11	2023-09-14	University Of Rochester	Cyclopeptibodies and uses thereof
IL315508A (en)	2022-03-17	2024-11-01	Seagen Inc	Camptothecin conjugates
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
CA3249442A1 (en)	2022-04-18	2025-06-17	Hanmi Pharm. Co., Ltd.	GLUCAGON-TYPE PEPTIDE-2 POLYTHERAPY WITH INSULIN-TROPIC PEPTIDE, ALPHA TUMOR NECROSIS FACTOR INHIBITOR, OR BOTH FOR THE PREVENTION OR TREATMENT OF INTESTINAL DISEASES
US20230357381A1 (en)	2022-04-26	2023-11-09	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
JP2025514858A (ja)	2022-04-29	2025-05-09	アストラゼネカ・ユーケイ・リミテッド	ＳＡＲＳ－ＣｏＶ－２抗体、及びその使用方法
US20240117021A1 (en)	2022-06-15	2024-04-11	Bioverativ Usa Inc.	Anti-complement c1s antibody formulation
CA3258000A1 (en)	2022-06-15	2023-12-21	argenx BV	FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
IL317947A (en)	2022-06-24	2025-02-01	Bioverativ Usa Inc	Complementary disease treatment methods
GB2635291A (en)	2022-07-01	2025-05-07	Alk Abello As	Displacers of IgE-FCERI
CA3262035A1 (en)	2022-07-15	2024-01-18	Janssen Biotech, Inc.	BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
EP4561613A1 (en)	2022-07-27	2025-06-04	Teneobio, Inc.	Mesothelin binding proteins and uses thereof
JP2025524986A (ja)	2022-07-27	2025-08-01	メディボストンリミテッド	オーリスタチン誘導体およびそのコンジュゲート
IL318625A (en)	2022-07-29	2025-03-01	Regeneron Pharma	Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
CA3263494A1 (en)	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE
JP2025525792A (ja)	2022-07-29	2025-08-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	トランスフェリン受容体１に対して再標的化されるウイルス粒子
US11773160B1 (en)	2022-08-05	2023-10-03	Anaveon AG	Immune-stimulating IL-2 fusion proteins
EP4568700A2 (en)	2022-08-09	2025-06-18	QLSF Biotherapeutics, Inc.	Antibodies binding to clec12a
CA3266599A1 (en)	2022-09-07	2024-11-07	Quantitative Biosciences, Inc.	UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
WO2024067401A1 (zh)	2022-09-26	2024-04-04	中美华世通生物医药科技(武汉)股份有限公司	包含Fc-高级脂肪酸链的超长效平台
EP4598958A1 (en)	2022-10-05	2025-08-13	Amgen Inc.	Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
IL320016A (en)	2022-11-04	2025-06-01	Regeneron Pharma	Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
AU2023379457A1 (en)	2022-11-14	2025-05-15	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024107759A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
WO2024129756A1 (en)	2022-12-13	2024-06-20	Seagen Inc.	Site-specific engineered cysteine antibody drug conjugates
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
AU2023408268A1 (en)	2022-12-23	2025-07-10	Hanmi Pharm. Co., Ltd.	Formulations comprising immune stimulating IL-2 analog conjugates
JP2026501948A (ja)	2022-12-23	2026-01-19	ハンミファーマシューティカルカンパニーリミテッド	Ｇｌｐ－２誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物
WO2024150074A2 (en)	2023-01-13	2024-07-18	Takeda Pharmaceutical Company Limited	Coronavirus antibodies and therapeutic uses thereof
CN121079323A (zh)	2023-02-21	2025-12-05	特尼奥生物股份有限公司	c-Kit结合蛋白、嵌合抗原受体及其用途
EP4673469A1 (en)	2023-03-02	2026-01-07	Alloy Therapeutics, Inc.	Anti-cd22 antibodies and uses thereof
KR20240137492A (ko)	2023-03-07	2024-09-20	한미약품 주식회사	암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법
JP2026509259A (ja)	2023-03-07	2026-03-17	ハンミファーマシューティカルカンパニーリミテッド	インターロイキン２アナログ又はその結合体を含む癌予防又は治療用薬学的組成物
WO2024194686A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024200854A1 (en)	2023-03-31	2024-10-03	Alk-Abelló A/S	Allergen binding antibodies suitable for treating tree pollen allergies
CN121152802A (zh)	2023-04-18	2025-12-16	魁尔斯弗生物治疗股份有限公司	与ly6g6d结合的抗体
CN121794380A (zh)	2023-06-27	2026-04-03	艾维迪提生物科学公司	使用prkag2靶向性抗体-寡核苷酸缀合物的组合物和方法
WO2025007063A1 (en)	2023-06-30	2025-01-02	Avidity Biosciences, Inc.	Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
AU2024317483A1 (en)	2023-07-28	2026-01-29	Regeneron Pharmaceuticals, Inc.	Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
US20250049896A1 (en)	2023-07-28	2025-02-13	Regeneron Pharmaceuticals, Inc.	Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
WO2025037108A2 (en)	2023-08-15	2025-02-20	Board Of Trustees Of The Leland Stanford Junior University	Modified thrombopoietin
US20250101101A1 (en)	2023-09-01	2025-03-27	iTeos Belgium SA	Anti-trem2 antibodies and methods of use
WO2025054181A1 (en)	2023-09-05	2025-03-13	Seagen Inc.	Targeted degrader molecules and ligand drug conjugates thereof
WO2025059215A1 (en)	2023-09-12	2025-03-20	Aadigen, Llc	Methods and compositions for treating or preventing cancer
TW202517301A (zh)	2023-10-06	2025-05-01	美商思進公司	用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
WO2025090774A1 (en)	2023-10-24	2025-05-01	Seagen Inc.	Chemotherapeutic compounds and methods of use
WO2025104604A1 (en)	2023-11-14	2025-05-22	Janssen Pharmaceuticals, Inc.	Anti-respiratory syncytial virus antibodies and uses thereof
WO2025128343A1 (en)	2023-12-11	2025-06-19	Just-Evotec Biologics, Inc.	Protein expression using trans-splicing and split selectable markers
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en)	2023-12-20	2025-06-26	argenx BV	Fcrn/hsa-binding molecules and methods of use
WO2025149947A1 (en)	2024-01-12	2025-07-17	Seagen Inc.	Antibody-drug conjugates
WO2025155877A2 (en)	2024-01-18	2025-07-24	The Regents Of The University Of California	Antibodies binding to pad4 and uses thereof
TW202600608A (zh)	2024-02-27	2026-01-01	美商必治妥美雅史谷比公司	抗ｃｅａｃａｍ５抗體及其用途
EP4658320A1 (en)	2024-02-27	2025-12-10	Bristol-Myers Squibb Company	Anti-ceacam5 antibody drug conjugates
WO2025193454A1 (en)	2024-03-01	2025-09-18	Prelude Therapeutics Incorporated	Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
US20250361297A1 (en)	2024-03-12	2025-11-27	Adaptam Therapeutics, S.L.	Anti- siglec-15 binding molecules and methods of use
TW202602940A (zh)	2024-04-09	2026-01-16	美商安進公司	激動性抗ｉｌ－２ｒｂｇ重鏈抗體
TW202544034A (zh)	2024-05-06	2025-11-16	美商榮都醫療公司	結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
WO2026006492A2 (en)	2024-06-25	2026-01-02	Ypsilon Therapeutics, Inc.	Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-wt1/hla-a2 antibody and uses thereof
WO2026006494A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-cd3 antibodies and uses thereof
WO2026058155A1 (en)	2024-09-11	2026-03-19	Novartis Ag	Antibodies targeting il-31

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3095168B2 (ja) *	1988-02-05	2000-10-03	エル．モリソン，シェリー	ドメイン‐変性不変部を有する抗体
WO1993022332A2 (en) *	1992-04-24	1993-11-11	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994004689A1 (en) *	1992-08-14	1994-03-03	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Recombinant toxin with increased half-life

1997
- 1997-03-03 JP JP53348897A patent/JP4046354B2/ja not_active Expired - Fee Related
- 1997-03-03 EP EP97907993A patent/EP0904107B1/en not_active Expired - Lifetime
- 1997-03-03 CA CA002249195A patent/CA2249195A1/en not_active Abandoned
- 1997-03-03 WO PCT/US1997/003321 patent/WO1997034631A1/en not_active Ceased
- 1997-03-03 AT AT97907993T patent/ATE279947T1/de not_active IP Right Cessation
- 1997-03-03 DE DE69731289T patent/DE69731289D1/de not_active Expired - Lifetime
- 1997-03-03 AU AU19850/97A patent/AU728657B2/en not_active Ceased

Also Published As

Publication number	Publication date
JP4046354B2 (ja)	2008-02-13
EP0904107B1 (en)	2004-10-20
WO1997034631A1 (en)	1997-09-25
AU1985097A (en)	1997-10-10
DE69731289D1 (de)	2004-11-25
CA2249195A1 (en)	1997-09-25
AU728657B2 (en)	2001-01-18
JP2000507816A (ja)	2000-06-27
EP0904107A1 (en)	1999-03-31

Legal Events

Date	Code	Title	Description
2005-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE279947T1 (de)	2004-11-15	Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1993022332A3 (en)	1994-02-17	Recombinant production of immunoglobulin-like domains in prokaryotic cells
PL415463A1 (pl)	2016-04-25	Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
EA200001023A1 (ru)	2001-06-25	Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE522610T1 (de)	2011-09-15	Menschliche, metabotrope glutamatrezeptor- subtypen (hmr6) und verwandte dns-verbindungen
KR950702635A (ko)	1995-07-29	감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
CY1112334T1 (el)	2015-12-09	Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
ATE112687T1 (de)	1994-10-15	Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
PT96097A (pt)	1991-09-30	Processo para a preparacao de antigene de toxoplasma gondii bem como de meios de diagnostico, vacinas e anticorpos deles derivados
DE69931284D1 (de)	2006-06-14	Menschliches Neurotrimin-Homolog
WO2001064913A3 (en)	2002-04-18	Cell cycle proteins associated with rad9, compositions and methods of use
WO2000043419A3 (en)	2001-02-15	Exocytosis pathway proteins and methods of use
ATE335005T1 (de)	2006-08-15	Menschliches protein mit in vitro antiproliferativer aktivität.
ATE290549T1 (de)	2005-03-15	Ing2, ein mit iaps assoziiertes zellzyklusprotein,sowie zusammensetzungen, verfahren und verwendungen
DE59914878D1 (de)	2008-11-13	Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
WO2000055192A3 (de)	2002-04-18	Hämocyanin und dafür kodierende nukleinsäuresequenz
SE9804491D0 (sv)	1998-12-22	Novel fibronectin-binding protein
DE69931282D1 (de)	2006-06-14	Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
PT1241185E (pt)	2005-04-29	Acido nucleico que e amplificado em tumores humanos e materiais e metodos relacionados
ATE380864T1 (de)	2007-12-15	Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
DE69927190D1 (de)	2005-10-13	Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
ATE405590T1 (de)	2008-09-15	Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure
ATE404585T1 (de)	2008-08-15	Menschliches synaptogyrin-ähnliches protein und dafür kodierende nukleinsäure
ATE402954T1 (de)	2008-08-15	Menschliches a33-antigen-ähnliches protein und dafür kodierende nukleinsäure
ATE492640T1 (de)	2011-01-15	Loslösendes protein 5 - ucp5